Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.
- Published In:
- Diabetes, obesity & metabolism, 24(1), 94-105 (2022)
- Authors:
- Wharton, Sean(7), Calanna, Salvatore, Davies, Melanie(3), Dicker, Dror, Goldman, Bryan, Lingvay, Ildiko, Mosenzon, Ofri, Rubino, Domenica M, Thomsen, Mette, Wadden, Thomas A, Pedersen, Sue D
- Database ID:
- RPEP-06589
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06589APA
Wharton, Sean; Calanna, Salvatore; Davies, Melanie; Dicker, Dror; Goldman, Bryan; Lingvay, Ildiko; Mosenzon, Ofri; Rubino, Domenica M; Thomsen, Mette; Wadden, Thomas A; Pedersen, Sue D. (2022). Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.. Diabetes, obesity & metabolism, 24(1), 94-105. https://doi.org/10.1111/dom.14551
MLA
Wharton, Sean, et al. "Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.." Diabetes, 2022. https://doi.org/10.1111/dom.14551
RethinkPeptides
RethinkPeptides Research Database. "Gastrointestinal tolerability of once-weekly semaglutide 2.4..." RPEP-06589. Retrieved from https://rethinkpeptides.com/research/wharton-2022-gastrointestinal-tolerability-of-onceweekly
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.